Bruker Corporation (BRKR)
| Market Cap | 8.70B +51.9% |
| Revenue (ttm) | 3.50B +1.7% |
| Net Income | -106.90M |
| EPS | -0.70 |
| Shares Out | 152.36M |
| PE Ratio | n/a |
| Forward PE | 25.46 |
| Dividend | $0.20 (0.35%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | 1,921,320 |
| Open | 60.00 |
| Previous Close | 62.00 |
| Day's Range | 56.00 - 60.17 |
| 52-Week Range | 32.37 - 66.98 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 63.83 (+11.85%) |
| Earnings Date | Nov 4, 2026 |
About BRKR
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BRKR stock is "Buy." The 12-month stock price target is $63.83, which is an increase of 11.85% from the latest price.
News
Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4,...
Bruker downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Casey Woodring downgraded Bruker (BRKR) to Neutral from Overweight with an unchanged price target of $60. The firm is “incrementally more cautious” on the company’s outlook over the…
Bruker price target raised to $62 from $60 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $62 from $60 and keeps a Hold rating on the shares. The firm adjusted targets in the life science…
Bruker price target raised to $70 from $58 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Bruker (BRKR) to $70 from $58 and keeps an Overweight rating on the shares. The firm adjusted targets in the…
Bruker announces seminal bioRxiv preprint
Bruker (BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Marku...
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolu...
Bruker price target raised to $72 from $70 at Guggenheim
Guggenheim raised the firm’s price target on Bruker (BRKR) to $72 from $70 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
Bruker price target raised to $80 from $60 at Leerink
Leerink raised the firm’s price target on Bruker (BRKR) to $80 from $60 and keeps an Outperform rating on the shares. The firm cites order book and emerging AI Bio…
Bruker announces timsUltra AIP, timsOmni workflows for drug discovery
At the Human Proteome Organization World Congress 2026, Bruker (BRKR) Corporation announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, m...
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows fo...
Bruker Transcript: Bank of America Global Healthcare Conference
Order growth in China, biopharma, and semi-metrology drove strong bookings, while U.S. academic funding remained weak but is showing signs of improvement for 2027. AI is expected to be a major growth driver for advanced research tools, and ongoing cost-saving programs and recurring revenue expansion are set to support margin growth.
Bruker announces over $6M multi-system order from UC Berkeley
Bruker (BRKR) Corporation announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance instrumentation at the Pines Magnetic Resonance Center. T...
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Re...
Bruker Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted a strategic focus on deep tech, diagnostics, and advanced multi-omics tools, with AI and automation poised to drive significant growth from 2027 onward. Strong order growth in biopharma, semiconductors, and China, along with innovation in diagnostics and spatial biology, positions the business for robust long-term performance.
Bruker Transcript: Wells Fargo 21st Annual Healthcare Conference
Reorganization and acquisitions are integrating NMR, mass spectrometry, and humanized systems for advanced drug discovery and AI. Strong financials show robust order growth in China and tech markets, though revenue is delayed by complex contracts. Proteomics, AI automation, and new partnerships drive leadership in biological analysis.
Bruker assumed with a Neutral at UBS
UBS assumed coverage of Bruker (BRKR) with a Neutral rating and $65 price target Despite enthusiasm for AI-driven demand in the semiconductor business, only some of that segment is poised…
Bruker Corporation to Present at Upcoming Investor Conferences
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today that its senior leadership will present at the following conferences: Wells Fargo 21st Annual Healt...
Bruker, Luvata enter strategic collaboration
Bruker (BRKR) Energy & Supercon Technologies, a segment of Bruker, and Luvata Materials & Solutions, a Business Unit of Luvata Group, announced a strategic collaboration to support the growing demand…
BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion
HANAU, Germany--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (Nasdaq: BRKR), and Luvata Materials & Solutions, a Business Unit of Luva...
Bruker announces strategic collaboration with Atinary Technologies
Bruker (BRKR) Corporation announced an expanded strategic collaboration with Atinary Technologies. Financial details were not disclosed. Atinary intends to integrate Chemspeed configurable laboratory ...
Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
BOSTON--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technol...
Bruker announces majority investment in MIMETAS B.V.
Bruker (BRKR) announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment ...
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced...
Bruker price target raised to $50 from $45 at Stifel
Stifel raised the firm’s price target on Bruker (BRKR) to $50 from $45 and keeps a Hold rating on the shares.
Bruker price target lowered to $53 from $60 at Citi
Citi lowered the firm’s price target on Bruker (BRKR) to $53 from $60 and keeps a Neutral rating on the shares.